{"id":"https://openalex.org/W3176942856","doi":"https://doi.org/10.2337/db21-792-p","title":"792-P: Comparative Safety of Empagliflozin in Routine Care Patients: Interim Results from the Empagliflozin Comparative Effectiveness and Safety (EMPRISE) Study","display_name":"792-P: Comparative Safety of Empagliflozin in Routine Care Patients: Interim Results from the Empagliflozin Comparative Effectiveness and Safety (EMPRISE) Study","publication_year":2021,"publication_date":"2021-06-01","ids":{"openalex":"https://openalex.org/W3176942856","doi":"https://doi.org/10.2337/db21-792-p","mag":"3176942856"},"language":"en","primary_location":{"id":"doi:10.2337/db21-792-p","doi":"https://doi.org/10.2337/db21-792-p","is_oa":false,"landing_page_url":"https://doi.org/10.2337/db21-792-p","pdf_url":null,"source":{"id":"https://openalex.org/S129060628","display_name":"Diabetes","issn_l":"0012-1797","issn":["0012-1797","1939-327X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320274","host_organization_name":"American Diabetes Association","host_organization_lineage":["https://openalex.org/P4310320274"],"host_organization_lineage_names":["American Diabetes Association"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetes","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5044474781","display_name":"Elisabetta Patorno","orcid":"https://orcid.org/0000-0002-8809-9898","observed_orcids":["https://orcid.org/0000-0002-8809-9898"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"ELISABETTA PATORNO","raw_affiliation_strings":["Boston, MA, Birmingham, AL, Ingelheim, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Boston, MA, Birmingham, AL, Ingelheim, Germany","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5074777366","display_name":"Helen Tesfaye","orcid":"https://orcid.org/0000-0002-6264-2813","observed_orcids":["https://orcid.org/0000-0002-6264-2813"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"HELEN TESFAYE","raw_affiliation_strings":["Boston, MA, Birmingham, AL, Ingelheim, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Boston, MA, Birmingham, AL, Ingelheim, Germany","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5076997901","display_name":"Deborah J. Wexler","orcid":"https://orcid.org/0000-0001-6979-402X","observed_orcids":["https://orcid.org/0000-0001-6979-402X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"DEBORAH J. WEXLER","raw_affiliation_strings":["Boston, MA, Birmingham, AL, Ingelheim, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Boston, MA, Birmingham, AL, Ingelheim, Germany","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5037322697","display_name":"Robert J. Glynn","orcid":"https://orcid.org/0000-0002-0697-8996","observed_orcids":["https://orcid.org/0000-0002-0697-8996"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"ROBERT GLYNN","raw_affiliation_strings":["Boston, MA, Birmingham, AL, Ingelheim, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Boston, MA, Birmingham, AL, Ingelheim, Germany","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5044094148","display_name":"Mehdi Najafzadeh","orcid":"https://orcid.org/0000-0003-4503-1057","observed_orcids":["https://orcid.org/0000-0003-4503-1057"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"MEHDI NAJAFZADEH","raw_affiliation_strings":["Boston, MA, Birmingham, AL, Ingelheim, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Boston, MA, Birmingham, AL, Ingelheim, Germany","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5030822229","display_name":"Lily Gui Bessette","orcid":"https://orcid.org/0000-0003-1088-8579","observed_orcids":["https://orcid.org/0000-0003-1088-8579"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"LILY G. BESSETTE","raw_affiliation_strings":["Boston, MA, Birmingham, AL, Ingelheim, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Boston, MA, Birmingham, AL, Ingelheim, Germany","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5047891240","display_name":"Heidi Zakoul","orcid":"https://orcid.org/0009-0008-3022-9013","observed_orcids":["https://orcid.org/0009-0008-3022-9013"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"HEIDI ZAKOUL","raw_affiliation_strings":["Boston, MA, Birmingham, AL, Ingelheim, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Boston, MA, Birmingham, AL, Ingelheim, Germany","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5026499631","display_name":"Lisette Koeneman","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"LISETTE KOENEMAN","raw_affiliation_strings":["Boston, MA, Birmingham, AL, Ingelheim, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Boston, MA, Birmingham, AL, Ingelheim, Germany","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5037108542","display_name":"Anouk D\u00e9ruaz\u2010Luyet","orcid":"https://orcid.org/0000-0001-7396-7392","observed_orcids":["https://orcid.org/0000-0001-7396-7392"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"ANOUK DERUAZ-LUYET","raw_affiliation_strings":["Boston, MA, Birmingham, AL, Ingelheim, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Boston, MA, Birmingham, AL, Ingelheim, Germany","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5004416630","display_name":"Sebastian Schneewei\u00df","orcid":"https://orcid.org/0000-0003-2575-467X","observed_orcids":["https://orcid.org/0000-0003-2575-467X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"SEBASTIAN SCHNEEWEISS","raw_affiliation_strings":["Boston, MA, Birmingham, AL, Ingelheim, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Boston, MA, Birmingham, AL, Ingelheim, Germany","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":1,"citation_normalized_percentile":{"value":0.12395422,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":90,"max":94},"biblio":{"volume":"70","issue":"Supplement_1","first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10198","display_name":"Heart Failure Treatment and Management","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10560","display_name":"Diabetes Management and Research","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/empagliflozin","display_name":"empagliflozin","score":0.996999979019165},{"id":"https://openalex.org/keywords/dpp-4-inhibitors","display_name":"DPP-4 inhibitors","score":0.8650000095367432},{"id":"https://openalex.org/keywords/type-2-diabetes","display_name":"type 2 diabetes","score":0.9089999794960022},{"id":"https://openalex.org/keywords/drug-safety","display_name":"drug safety","score":0.8889999985694885},{"id":"https://openalex.org/keywords/comparative-effectiveness","display_name":"comparative effectiveness","score":0.7369999885559082},{"id":"https://openalex.org/keywords/lower-extremity-amputation","display_name":"lower limb amputation","score":0.8859999775886536},{"id":"https://openalex.org/keywords/bone-fractures","display_name":"bone fractures","score":0.8069999814033508},{"id":"https://openalex.org/keywords/diabetic-ketoacidosis","display_name":"diabetic ketoacidosis","score":0.9909999966621399},{"id":"https://openalex.org/keywords/acute-kidney-injury","display_name":"acute kidney injury","score":0.9990000128746033},{"id":"https://openalex.org/keywords/real-world-evidence","display_name":"real-world evidence","score":0.5849999785423279},{"id":"https://openalex.org/keywords/medicare-claims-data","display_name":"Medicare claims data","score":0.625},{"id":"https://openalex.org/keywords/usual-care","display_name":"usual care","score":0.4569999873638153},{"id":"https://openalex.org/keywords/sglt2-inhibitors","display_name":"SGLT2 inhibitors","score":0.7480000257492065},{"id":"https://openalex.org/keywords/cardiovascular-disease","display_name":"cardiovascular disease","score":0.4050000011920929},{"id":"https://openalex.org/keywords/health-care-utilization","display_name":"health care utilization","score":0.5640000104904175},{"id":"https://openalex.org/keywords/propensity-score-matching","display_name":"propensity score matching","score":0.6510000228881836},{"id":"https://openalex.org/keywords/pharmacoepidemiology","display_name":"pharmacoepidemiology","score":0.6470000147819519}],"concepts":[{"id":"https://openalex.org/C2775887513","wikidata":"https://www.wikidata.org/wiki/Q5373824","display_name":"Empagliflozin","level":4,"score":0.9863384962081909},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8604600429534912},{"id":"https://openalex.org/C2780652884","wikidata":"https://www.wikidata.org/wiki/Q5323607","display_name":"EMPA","level":3,"score":0.62422776222229},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5220258831977844},{"id":"https://openalex.org/C2781308992","wikidata":"https://www.wikidata.org/wiki/Q2526479","display_name":"Liraglutide","level":4,"score":0.4851296842098236},{"id":"https://openalex.org/C2777180221","wikidata":"https://www.wikidata.org/wiki/Q3025883","display_name":"Type 2 diabetes","level":3,"score":0.4613637328147888},{"id":"https://openalex.org/C555293320","wikidata":"https://www.wikidata.org/wiki/Q12206","display_name":"Diabetes mellitus","level":2,"score":0.45774051547050476},{"id":"https://openalex.org/C194828623","wikidata":"https://www.wikidata.org/wiki/Q2861470","display_name":"Emergency medicine","level":1,"score":0.3264450430870056},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.10295233130455017},{"id":"https://openalex.org/C138411078","wikidata":"https://www.wikidata.org/wiki/Q911272","display_name":"Electron microprobe","level":2,"score":0.0},{"id":"https://openalex.org/C199289684","wikidata":"https://www.wikidata.org/wiki/Q83353","display_name":"Mineralogy","level":1,"score":0.0},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.2337/db21-792-p","doi":"https://doi.org/10.2337/db21-792-p","is_oa":false,"landing_page_url":"https://doi.org/10.2337/db21-792-p","pdf_url":null,"source":{"id":"https://openalex.org/S129060628","display_name":"Diabetes","issn_l":"0012-1797","issn":["0012-1797","1939-327X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320274","host_organization_name":"American Diabetes Association","host_organization_lineage":["https://openalex.org/P4310320274"],"host_organization_lineage_names":["American Diabetes Association"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetes","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":1.0}],"study_designs":[{"display_name":"Observational Study","id":"https://openalex.org/study-designs/observational-study"}],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W3035241156","https://openalex.org/W4281768514","https://openalex.org/W3010207927","https://openalex.org/W2948182500","https://openalex.org/W3210055886","https://openalex.org/W4393054462","https://openalex.org/W3176817582","https://openalex.org/W3084742701","https://openalex.org/W4313531576","https://openalex.org/W4398171858"],"abstract_inverted_index":{"In":[0,66,183],"the":[1,8,46,186],"EMPA-REG":[2],"OUTCOME":[3],"trial":[4],"empagliflozin":[5],"(EMPA)":[6],"reduced":[7],"risk":[9,145,152,167],"of":[10,34,52,81,99,138,146,153,168,188,216],"cardiovascular":[11,29],"death,":[12],"all-cause":[13],"mortality,":[14],"and":[15,27,49,59,111,121,148,164,268,274],"hospitalization":[16,109,115],"for":[17,129],"heart":[18],"failure":[19],"in":[20,36,75,196],"patients":[21,85],"with":[22,88,124,180,192,198],"type":[23],"2":[24,60],"diabetes":[25],"(T2D)":[26],"established":[28],"disease.":[30],"The":[31],"comparative":[32],"safety":[33,48,194],"EMPA":[35,91,141,189],"routine":[37,184],"care":[38],"is":[39],"yet":[40],"to":[41],"be":[42],"established.":[43],"EMPRISE":[44],"studies":[45],"effectiveness,":[47],"healthcare":[50],"utilization":[51],"EMPA,":[53],"based":[54],"on":[55],"data":[56,71],"from":[57,72],"Medicare":[58],"U.S.":[61],"commercial":[62],"claims":[63],"datasets":[64],"(2014-2019).":[65],"an":[67,150],"interim":[68],"analysis":[69],"using":[70],"2014-2018":[73],"(2014-2017":[74],"Medicare),":[76],"we":[77],"identified":[78],"55,580":[79],"pairs":[80],"1:1":[82],"propensity":[83],"score-matched":[84],"\u226518":[86],"years":[87],"T2D":[89],"initiating":[90],"or":[92],"a":[93,134,165,193],"DPP4":[94],"inhibitor":[95],"(DPP4i).":[96],"Safety":[97],"outcomes":[98],"interest":[100],"included":[101],"lower-limb":[102],"amputations":[103],"(LLA),":[104],"bone":[105],"fractures,":[106,149],"diabetic":[107],"ketoacidosis":[108],"(DKA),":[110],"acute":[112],"kidney":[113],"injury":[114],"(AKI).":[116],"We":[117],"estimated":[118],"pooled":[119],"HR":[120],"RD/1000":[122],"PY":[123],"their":[125],"95%":[126],"CI":[127],"adjusting":[128],">140":[130],"baseline":[131],"covariates.":[132],"Over":[133],"mean":[135],"follow":[136],"up":[137],"6.3":[139],"months,":[140],"initiators":[142],"had":[143],"similar":[144],"LLA":[147],"increased":[151],"DKA":[154],"[HR,":[155,170],"2.01":[156],"(1.37-2.95);":[157],"RD,":[158,173],"1.44":[159],"(0.72,2.17)":[160],"per":[161,176],"1000":[162,177],"PY],":[163,178],"decreased":[166],"AKI":[169],"0.66":[171],"(0.59-0.74);":[172],"-8.59":[174],"(-10.93,-6.25)":[175],"compared":[179],"DPP4i":[181],"(Table).":[182],"care,":[185],"initiation":[187],"was":[190],"associated":[191],"profile":[195],"line":[197],"documented":[199],"information.View":[200],"largeDownload":[201,203],"slideView":[202],"slide":[204],"DisclosureE.":[205],"Patorno:":[206],"Research":[207,237,242],"Support;":[208,238],"Self;":[209,222,232,239,256,265,271,279],"Boehringer":[210,280],"Ingelheim":[211,281],"International":[212],"GmbH,":[213],"National":[214],"Institutes":[215],"Health.":[217],"S.":[218],"Schneeweiss:":[219],"Other":[220],"Relationship;":[221],"Aetion.":[223],"H.":[224,259],"Tesfaye:":[225],"None.":[226,251,261],"D.":[227],"J.":[228],"Wexler:":[229],"Board":[230],"Member;":[231],"Novo":[233],"Nordisk.":[234],"R.":[235],"Glynn:":[236],"AstraZeneca,":[240],"Kowa":[241],"Institute,":[243],"Inc.,":[244],"Novartis":[245],"AG,":[246],"Pfizer":[247],"Inc.":[248,258],"M.":[249],"Najafzadeh:":[250],"L.":[252,262],"G.":[253],"Bessette:":[254],"Consultant;":[255],"Aetion,":[257],"Zakoul:":[260],"Koeneman:":[263],"Employee;":[264,278,284],"Eli":[266,272],"Lilly":[267,273],"Company,":[269],"Stock/Shareholder;":[270],"Company.":[275],"A.":[276],"Deruaz-luyet:":[277],"(Canada)":[282],"Ltd.,":[283],"Spouse/Partner;":[285],"Sanofi-Aventis":[286],"Deutschland":[287],"GmbH.":[288]},"counts_by_year":[{"year":2025,"cited_by_count":1}],"updated_date":"2026-09-27T08:07:27.782135","created_date":"2021-07-05T00:00:00"}